InsidersTradesSigma
Follow the Kymera Therapeutics, Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Kymera Therapeutics, Inc. has logged 153 reports. Market capitalisation: €9.1bn. The latest transaction was reported on 7 July 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Booth Bruce. The full history is free.
153
Insider Decl.
n/a
Thresholds
€2m
1 ops.
Buy Volume
€3m
139 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Kymera Therapeutics, Inc. Strong Buy (bullish), based on 21 analysts. Average price target: US$127.05.
44Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 7 July 2026
Declarations153 total
50,000 shares@ US$119.000.061% mcap39.3% of flowCommonSEC144:0001969223-26-000769
80,000 shares@ US$114.290.098% mcap100.0% of flowCommonSEC144:0001969223-26-000752
28,296 sharesCommon StockSEC:0001451612-26-000018:0
231,007 sharesCommon StockSEC:0001451612-26-000018:1
32,624 sharesCommon StockSEC:0001451612-26-000018:2
11,277 sharesCommon StockSEC:0001451612-26-000018:3
10,366 sharesCommon StockSEC:0001451612-26-000018:4
555 sharesCommon StockSEC:0001451612-26-000018:5
14,913 sharesCommon StockSEC:0001451612-26-000018:6
27,951 sharesCommon StockSEC:0001451612-26-000018:7
6,821 sharesCommon StockSEC:0001451612-26-000018:8
12,181 sharesCommon StockSEC:0001451612-26-000018:9
22,046 sharesCommon StockSEC:0001451612-26-000018:10
12,390 sharesCommon StockSEC:0001451612-26-000018:11
3,958 sharesCommon StockSEC:0001451612-26-000018:12
32,402 sharesCommon StockSEC:0001451612-26-000018:13
4,562 sharesCommon StockSEC:0001451612-26-000018:14
1,579 sharesCommon StockSEC:0001451612-26-000018:15
1,442 sharesCommon StockSEC:0001451612-26-000018:16
78 sharesCommon StockSEC:0001451612-26-000018:17
2,083 sharesCommon StockSEC:0001451612-26-000018:18
3,896 sharesCommon StockSEC:0001451612-26-000018:19
952 sharesCommon StockSEC:0001451612-26-000018:20
1,701 sharesCommon StockSEC:0001451612-26-000018:21
3,069 sharesCommon StockSEC:0001451612-26-000018:22
25 of 153 declarations
关于 Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc.（股票代码：KYMR）是一家在美国纳斯达克上市的临床阶段生物技术公司。公司总部位于马萨诸塞州沃特敦，专注于通过靶向蛋白质降解（TPD）重塑严重疾病的治疗方法。TPD是一种药物发现方法，旨在选择性地消除传统药物难以解决的致病蛋白质。Kymera的企业身份和科学战略围绕这一模式构建，管理层强调其发现引擎每年能够推动至少一个新项目进入临床试验。（[kymeratx.com](https://www.kymeratx.com/about-us/our-company/)） Kymera的核心业务是开发高度差异化、同类首创的小分子降解剂，主要关注免疫学和炎症性疾病。公司正努力将蛋白质降解的潜力转化为口服疗法，这可能为注射生物制剂或旧的作用机制提供方便且可能更有效的替代方案。其最先进的项目是KT-621，一种口服STAT6降解剂，目前正处于特应性皮炎和哮喘的2期试验中。Kymera还在2026年将口服IRF5降解剂KT-579推进到首次人体1期研究。此外，公司继续通过合作项目开展工作，包括与赛诺菲（Sanofi）的IRAK4合作，该合作优先考虑KT-485的未来开发。（[investors.kymeratx.com](https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-fourth-quarter-and-full-year-2025/)） 从竞争角度来看，Kymera在生物技术领域占据了一个创新利基市场，其中科学差异化、临床执行和数据质量对于长期价值创造至关重要。公司将自己定位为将口服降解剂从肿瘤学领域引入免疫学领域的先驱，并指出它将首个用于免疫疾病的口服小分子降解剂推进到临床试验。这种先行者形象很重要，因为TPD仍然是一个相对较新的治疗类别，Kymera正试图将自己确立为炎症和免疫介导疾病领域的领导者之一。（[kymeratx.com](https://www.kymeratx.com/about-us/our-company/)） Kymera的地理基地位于美国，其运营足迹集中在波士顿生物技术生态系统，但其临床项目旨在进行全球开发。近期亮点包括2025年12月报告的KT-621积极的1b期数据、KT-621获得FDA快速通道资格、2026年1月将BROADEN2 2b期试验扩展到青少年，以及2026年1月启动BREADTH 2b期哮喘研究。在融资方面，公司在2025年通过股权发行和与合作相关的现金流入加强了资产负债表，根据管理层说法，将其现金流延长至2028年下半年。（[investors.kymeratx.com](https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-fourth-quarter-and-full-year-2025/)）
